Drugs / Matrix-M1
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04961541 | Sep → Dec 2021 | COVID-19 | Novavax | Completed | No outcome recorded |
| Phase 1/2 | NCT02078674 | Mar 2014 → Jul 2015 | influenza | Novavax | Completed | No outcome recorded |
| Comparator or background therapy9 trials | ||||||
| Phase 0 | NCT05270265 Background | Feb 2022 → Jul 2023 | Plasmodium vivax malaria | University of Oxford | Terminated | No outcome recorded |
| Phase 1 | NCT04130282 Background | Sep 2019 → Sep 2020 | Plasmodium falciparum malaria | University of Oxford | Terminated | No outcome recorded |
| Phase 1 | NCT02572388 Comparator | Oct 2015 → Aug 2017 | malaria | University of Oxford | Completed | No outcome recorded |
| Phase 1/2 | NCT05683834 Background | Sep 2023 → Apr 2026 | infectious mononucleosis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1/2 | NCT05029856 Background | Feb → Aug 2022 | COVID-19 | Novavax | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT04201431 Background | Jan 2020 → Jul 2022 | Plasmodium vivax malaria | University of Oxford | Completed | Met primary |
| Phase 1/2 | NCT02925403 Comparator | Aug 2016 → Feb 2017 | malaria | University of Oxford | Completed | No outcome recorded |
| Phase 1/2 | NCT02905019 Comparator | Aug 2016 → Dec 2017 | malaria | University of Oxford | Completed | No outcome recorded |
| Phase 2 | NCT07147400 Background | Aug 2025 → Nov 2027 expected | malaria | Serum Institute of India Pvt. Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MATRIX-M1 | “Intramuscular (deltoid) injections of 3 μg SII B.1.351 and 50 μg Matrix-M1 Adjuvant” NCT05029856 ↗ |
| Modality | Other / unclassified | “a protein/adjuvant formulation (PvDBPII/Matrix-M™)” PMID 35664997 ↗ May 2022 |
| Route | Intramuscular | “High dose Monovalent Avian Influenza VLP (H7N9) with High dose Matrix-M1™ adjuvant; IM; Day 0 and Day 21” NCT02078674 ↗ |